Juan Pasquau

TL;DR: A bundle orientated to improving adherence to evidence-based QCIs improved the management of patients with SAB and was associated with reduced mortality.

TL;DR: In this trial, 48 weeks of lopinavir-ritonavir monotherapy with reintroduction of nucleosides as needed was non-inferior to continuation of two nucleoside and lop Scandinavian-rit onavir in patients with prior stable suppression, however, episodes of low level viremia were more common in patients receiving monotherapy.

TL;DR: This consensus document defines the objectives of the PROA (namely, to improve the clinical results of patients with infections, to minimise the adverse events associated to the use of antimicrobials including the emergence and spread of antibiotic resistance), and provides recommendations for the implementation of these programs in Spanish hospitals.

TL;DR: Dual treatment with atazanavir-ritonavir plus lamivudine was effective, safe, and non-inferior to triple treatment in patients with an HIV-1 infection who are virologically suppressed who switch antiretroviral therapy because of toxic effects, intolerance, or simplification.

TL;DR: Treatment of VL with meglumine antimoniate or amphotericin B was shown to have similar efficacy and toxicity rates in Spanish HIV-infected patients, and the differences in the toxicity patterns could be useful in choosing one of these agents as first-line treatment.